11242017Headline:

Phoenix, Arizona

HomeArizonaPhoenix

Email Jackie Fedeli Jackie Fedeli on LinkedIn Jackie Fedeli on Twitter Jackie Fedeli on Facebook
Jackie Fedeli
Jackie Fedeli
Contributor • (215) 985-0300

Is Actos Still On The Market

2 comments

On June 15, 2011, the U.S. Food and Drug Administration (FDA) issued a safety alert informing the public that using the diabetes medication Actos for more than one year may be associated with bladder cancer. Many people who rely on Actos are wondering “Is Actos still on the Market?”

The FDA’s Safety Alert was not a recall. So, Actos is still on the market. The FDA’s warning did prompt a label change which went into effect in August 4, 2011. The new label now warns Actos users of increased risk of bladder cancer. These warnings, though not to be taken lightly by anyone using Actos, are especially geared towards long term and high dose users of Actos. The new label also warns against prescribing Actos for anyone with active bladder cancer, and strongly cautions prescribing the drug to patients with a prior history of bladder cancer.

While, there are no definitive answers as to how much is too much, the FDA will continue to evaluate data from an ongoing ten-year epidemiological study as well as a French Study and will continue to update the public when more information is available.

Actos is still available, by prescription, to treat Type II Diabetes. Anyone who is currently taking Actos or considering taking Actos or similar drugs including Actoplus met, Actoplus met XR, and duetact, should consult with their physician regarding the safety of their dosage, and their long-term treatment options. Talk to your doctor immediately if you are experiencing any symptoms of bladder cancer such as blood in your urine, or pain during urination.

2 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

  1. Reggie Corpus says:
    up arrow

    “The FDA’s warning did prompt a label change which went into effect in August 4, 2011.” Registrar Corp’s Drug Labeling and Ingredient Review service helps companies determine their drug’s likely classification and compliance with applicable labeling requirements. Registrar Corp cross references your labeling against thousands of pages within the Code of Federal Regulations as well as the Federal Register, CDER’s Listing of OTC Active Ingredients, Rulemaking History for Nonpresciption Products, Guidance Documents and Warning Letters issued by U.S. FDA. For more information visit http://www.registrarcorp.com/fda-drugs/labeling/regulations.jsp?lang=en

  2. up arrow

    Actos is produced by Takeda Industries and co-marketed by Eli Lilly.
    Eli Lilly Zyprexa can *cause* diabetes.
    I took Zyprexa olanzapine a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
    Eli Lilly’s #1 cash cow Zyprexa drug sale $65 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company Eli Lilly also is a big profiteer of diabetes treatment.
    (Actos works as an insulin *sensitizer*)
    Sooooo,Eli Lilly pushes a drug (Zyprexa) that can cause diabetes…. then turn around sell you the drugs (Actos) to treat the diabetes that in turn can cause cancer!
    What a terrible conflict of interest!
    — Daniel Haszard